1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Shuda Xia
Shuda Xia
Articles (220) 

Stocks That Fell to 3-Year Lows in the Week of Nov. 23

AT&T Inc., Altria Group Inc., Gilead Sciences Inc. and Westpac Banking Corp have declined to their respective 3-year lows

November 25, 2018 | About:

AT&T Inc. (NYSE:T), Altria Group Inc. (NYSE:MO), Gilead Sciences Inc. (NASDAQ:GILD) and Westpac Banking Corp. (NYSE:WBK) have declined to their three-year lows.

AT&T Inc. (NYSE:T) declined to $29.36

The prices of AT&T Inc. (NYSE:T) shares have declined to $29.36 on Nov. 23, which is only 1.7% above the 3-year low of $28.85.

AT&T Inc. an American multinational telecommunications conglomerate that is the second largest provider of mobile telephone services and the largest provider of fixed telephone services in the United States. It also provides broadband subscription television services through DirecTV.

AT&T Inc. has a market cap of $211.17 billion; its shares were traded around $29.36 with a P/E ratio of 5.57 and P/S ratio of 1.17. The trailing 12-month dividend yield of AT&T Inc. stocks is 6.81%. The forward dividend yield of AT&T Inc. stocks is 6.72%. AT&T Inc. had an annual average earnings growth of 1.60% over the past 10 years.

On Nov. 5 AT&T Inc. announced that it will be joining Prevas, a Swedish IT and engineering company, in a 3-year deal to help businesses apply AT&T’s secure IoT solutions to help Prevas customers get their connected products to market faster. Prevas will use AT&T’s IoT solutions to help its customers more easily access their smart operations and services.

Altria Group Inc. (NYSE:MO) declined to $53.72

The prices of Altria Group Inc. (NYSE:MO) shares have declined to $53.72 on Nov. 23, which is only 0.5% above the 3-year low of $53.47.

Altria Group Inc. is an American international tobacco corporation. The company is one of the world’s largest producers and marketers of cigarettes and other tobacco products. The company is the parent company of several companies, including Smokeless Tobacco Company Inc. and John Middleton Inc.

Altria Group Inc. has a market cap of $103.24 billion; its shares were traded around $53.72 with a P/E ratio of 9.59 and P/S ratio of 4.00. The trailing 12-month dividend yield of Altria Group Inc. stocks is 5.32%. The forward dividend yield of Altria Group Inc. stocks is 5.88%. Altria Group Inc. had an annual average earnings growth of 6.80% over the past 10 years.

On Oct. 25 Altria Group Inc. reported third quarter 2018 financial results. Net revenues for the quarter were $6.84 billion, a 1.6% increase compared to net revenues during the same quarter prior year. Reported diluted earnings per share for the quarter were $1.03, a 6.2% increase compared to diluted earnings per share during the same quarter prior year.

Gilead Sciences Inc. (NASDAQ:GILD) declined to $66.59

The prices of Gilead Sciences Inc. (NASDAQ:GILD) shares have declined to $66.59 on Nov. 23, which is only 4.2% above the 3-year low of $63.76.

Gilead Sciences Inc. is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. Some of the products that the company developed include AmBisome, Atripla, Cayston, Emtriva, and Flolan.

Gilead Sciences Inc. has a market cap of $87.21 billion; its shares were traded around $66.59 with a P/E ratio of 55.50 and P/S ratio of 3.92. The trailing 12-month dividend yield of Gilead Sciences Inc. stocks is 3.35%. The forward dividend yield of Gilead Sciences Inc. stocks is 3.42%. Gilead Sciences Inc. had an annual average earnings growth of 31.00% over the past 10 years.

On Nov. 18 Gilead Sciences Inc. announced that the China National Medical Products Administration has approved of Vemlidy, a once-daily treatment for chronic hepatitis B in individuals aged 12 years and older. In clinical trials, Vemlidy demonstrated superior renal and bone laboratory safety parameters compared to Viread, another drug that Gilead has developed for hepatitis B.

Westpac Banking Corp. (NYSE:WBK) declined to $18.68

The prices of Westpac Banking Corp. (NYSE:WBK) shares have declined to $18.68 on Nov. 23, which is only 2.5% above the 3-year low of $18.22.

Westpac Banking Corp. is an Australian bank and financial services provider that is one of Australia’s “big four” banks. As of March 2018, the company has approximately 14 million customers and employs 40,000 people.

Westpac Banking Corp. has a market cap of $64.21 billion; its shares were traded around $18.68 with a P/E ratio of 11.18 and P/S ratio of 4.21. The trailing 12-month dividend yield of Westpac Banking Corp. stocks is 7.41%. The forward dividend yield of Westpac Banking Corp. stocks is 7.27%.

On Nov. 5 Westpac Banking Corp. reported full year 2018 financial results. Cash earnings for the company remained constant at $8.065 billion, while statutory net profits increased 1% from full year 2017 to $8.095 billion. Earnings per share decreased 1% from full year 2017 to 236.2 cents.

Disclosure: I do not own stock in any of the companies mentioned in the article.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Shuda Xia


User Generated Screeners


consciousinvestor311higher debt expensive
DANGORDONBOOK VALUE GROWTH RATE
doniemaherScreen #35 - ROC>25%, Div>3%
DANGORDON1-21-19 P/E<14
efredbac10yr Low PE
mathew94Insider Buys
cspunarJuniors 21Jan19
daftheaderasian growth plus dividend
DANGORDONTECH COS RATE OF RETURN
DANGORDONRETAIL COS RATE OF RETURN
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK